Biocon Faces 4% Drop in Stock Value as Subsidiary Offloads Branded Formulations Business to Eris Lifesciences
March 15 witnessed a decline of over 4% in Biocon’s shares, triggered by the news of its subsidiary, Biocon Biologics, divesting its India-branded formulation business to Eris Lifesciences, a prominent player in chronic therapy drugs, for a substantial sum of Rs 1,242 crore. The transaction, valued at an accretive multiple of 3.4 times revenue and … Read more